|
| Authors | Date | Study design | Sample size | Age (years) | Male (%) | Levels of serum phosphate (mg/dl) | Hypophosphatemia (%) | Criteria for hypophosphatemia | Outcomes significantly correlating with serum phosphorus | Laboratory parameters significantly correlating with serum phosphorus |
| (%) |
|
| Arenas et al. [28] | August 2020 | Cross-sectional | Total | 61 (100) | : | 45 (73) | vs. | N/A | N/A | N/A | N/A |
| ESRD patients, confirmed for COVID-19 | 34 (55.7) | : | 24 (70.6) |
| ESRD patients, suspected of COVID-19 | 27 (44.3) | : | 21 (77.8) |
|
| Chen et al. [26] | September 2021 | Cross-sectional | Total | 823 (100) | : | 412 (50.1) | 3.38 (2.91-3.78) | 60/637 (9.4) | Serum phosphate under 0.8 mmol/l (2.48 mg/dl) | AKI, death, longer hospitalization | Lower lymphocyte count, serum albumin, acid uric, higher LDH and CRP |
| Acute kidney injury | 44 (6) | : | 27 (61.4) | 2.51 (1.98-3.34) |
| No acute kidney injury | 779 (94) | : | 385 (49.4) | 3.41 (2.94-3.78) |
|
| Javdani et al. [29] | August 2020 | Cross-sectional | Total | 36 (100) | <30 years: 2 (5.6)
30-60 years: 18 (50)
≥60 years:16 (44.4) | 20 (55.6) | vs. | N/A | N/A | N/A | N/A |
| CORAD II and III | 5 (13.8) | N/A | N/A |
| CORAD IV and V | 31 (86.2) | N/A | N/A |
|
| Pal et al. [25] | January 2021 | Case-control | Total | 144 (100) | : | 68 (47) | vs. | N/A | N/A | N/A | N/A |
| Nonsevere | 72 (50) | Median (IQR): 36 (27-48.2)
: | 34 (48) |
| Healthy controls | 72 (50) | Median (IQR): 35 (25.2-45.2)
: | 34 (48) |
|
| Wang et al. [30] | September 2021 | Cross-sectional | Total | 435 (100) | 57 (41-68) | 200 (46) | 3.44 (2.97-3.87) | 33 (7.6) | Serum phosphate under 0.8 mmol/l (2.48 mg/dl) | Mortality | Lower lymphocyte count |
| Nonhypophosphatemia | 402 (92.4) | 56 (39-67) | 187 (46.5) | 3.5 (3.07-3.96) |
| Hypophosphatemia | 33 (7.6) | 67 (63-76) | 13 (39.4) | 2.26 () |
|
| Xue et al. [27] | March 2020 | Cross-sectional | Total | 32 (100) | : | 20 (62.5) | vs. | N/A | N/A | N/A | Absolute value of lymphocyte |
| Severe | 20 (62.5) | : | 12 (60) | 10 (50) |
| Ordinary | 12 (37.5) | : | 8 (66.7) | N/A |
|
| Yang et al. [31] | September 2020 | Cross-sectional | Total | 226 (100) | :
Median (IQR): 40 (28-54) | 137 (60.6) | N/A | 44 (19.5) | Serum phosphate under 0.85 mmol/l (2.65 mg/dl) | ICU admission, ICU stay, CT score, oxygen saturation, respiratory rate | ALT/AST, CRP, lactic acid, CK, Ca |
| Suspected COVID-19 | 122 (54) | Median (IQR): 35 (26-53) | 73 (59.8) | 13 (10.9) |
| Confirmed COVID-19 | Total | 104 (46) | Median (IQR): 44 (33-55) | 64 (61.5) | 30 (29.7) |
| Severe confirmed | 36 (35) | Median (IQR): 47 (41-64) | 24 (66.6) | 20 (57.1) |
| Moderate confirmed | 68 (65) | Median (IQR): 42 (33-52) | 39 (58.8) | 10 (15.2) |
|
